PNU-177864 hydrochloride
CAS No. 1783978-03-9
PNU-177864 hydrochloride( PNU-177864 (hydrochloride) )
Catalog No. M26387 CAS No. 1783978-03-9
PNU-177864 hydrochloride is a selective antagonist of D3 receptor with antischizophrenic activity.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
Size | Price / USD | Stock | Quantity |
5MG | 45 | Get Quote |
|
10MG | 68 | Get Quote |
|
25MG | 115 | Get Quote |
|
50MG | 173 | Get Quote |
|
100MG | 258 | Get Quote |
|
200MG | Get Quote | Get Quote |
|
500MG | Get Quote | Get Quote |
|
1G | Get Quote | Get Quote |
|
Biological Information
-
Product NamePNU-177864 hydrochloride
-
NoteResearch use only, not for human use.
-
Brief DescriptionPNU-177864 hydrochloride is a selective antagonist of D3 receptor with antischizophrenic activity.
-
DescriptionPNU-177864 hydrochloride is a selective antagonist of D3 receptor with antischizophrenic activity.(In Vivo):In Sprague-Dawley rats, PNU-177864 hydrochloride (8-200 mg/kg; gavage) induces phospholipidosis in unusual target organs including epididymis, hair follicles and pituitary.
-
In Vitro——
-
In VivoPNU-177864 (12.5-200 mg/kg; oral gavage; daily; for 2-4 weeks; Sprague-Dawley rats) treatment induces phospholipidosis in unusual target organs in dogs or rats including epididymis, pituitary, and hair follicles. Animal Model:Male and female Sprague-Dawley rats (8-9-week-old)Dosage:12.5 mg/kg, 50 mg/kg (for 2 weeks), or 200 mg/kg; 8 mg/kg, 25 mg/kg, or 80 mg/kg (for 4 weeks)Administration:Oral gavage; daily; for 2-4 weeks Result:Induced phospholipidosis in unusual target organs in dogs or rats including epididymis, pituitary, and hair follicles.
-
SynonymsPNU-177864 (hydrochloride)
-
PathwayGPCR/G Protein
-
TargetDopamine Receptor
-
RecptorVHL
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1783978-03-9
-
Formula Weight438.89
-
Molecular FormulaC18H22ClF3N2O3S
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESCl.O=S(=O)(NC1=CC=C(C=C1)CCNCCC)C2=CC=C(OC(F)(F)F)C=C2
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.An S, et al. Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs. EBioMedicine. 2018 Oct;36:553-562.
molnova catalog
related products
-
Tetrabenazine
Tetrabenazine is a VMAT-inhibitor used for treatment of hyperkinetic movement disorder.
-
JNJ-37822681 dihydro...
JNJ-37822681 dihydrochloride is a novel, highly selective dopamine D? receptor antagonist characterized by a rapid dissociation rate from the dopamine D? receptor.
-
N,N-Dimethylglycine
N, N-Dimethylglycine is used as an athletic performance enhancer and immunostimulant. It is also used in the treatment of autism, epilepsy and mitochondrial disease.